US generic business to face pricing pressure for 12 months: ICRA

The US generic business has been a significant contributor to growth and profitability for Indian generic companies over the last decade, but is facing a slowdown over the last couple of years.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news